JSR Corporation (hereinafter “JSR”; Representative Director, CEO and President: Tetsuro Hori) today announced the completion of procedures related to the transfer of its in vitro diagnostics business and in vitro diagnostics materials business.

As resolved by JSR’s Board of Directors on April 22, 2025, JSR established JSR-01 Corporation (hereinafter the “newly established company”) and transferred to it the in vitro diagnostics business, including its subsidiaries Medical & Biological Laboratories Co., Ltd. (President and Representative Director: Hiroki Ito) and JSR Life Sciences Corporation (President and Representative Director: Eiji Takamoto). JSR also executed a share transfer agreement to transfer all outstanding shares of the newly established company to Tokuyama Corporation (hereinafter “Tokuyama”; President and Representative Director: Hiroshi Yokota).

Under this agreement, the business was succeeded by the newly established company through an absorption-type company split, and all shares of the newly established company were transferred to Tokuyama on October 1, 2025. For details regarding the newly established company’s trade name, address, and representative, please refer to Tokuyama’s press release issued today.

A summary of the absorption-type company split and the share transfer is provided in Tokuyama’s April 22, 2025 press release, “Notice Concerning Acquisition of Shares (Making Subsidiary) of Newly Established Company to Take Over In Vitro Diagnostic Products Business and In Vitro Diagnostic Products Materials Business of JSR Corporation through Absorption-Type Company Split.”

Future announcements regarding products and services of the in vitro diagnostics business and in vitro diagnostics materials business will be provided by Medical & Biological Laboratories, Inc.

JSR remains committed to establishing a solid business foundation and enhancing sustainable value creation as a company trusted by all stakeholders.